Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A 3rd View: Examining the market potential of DBV's Viaskin Patch and Aimmune’s AR-101 with an allergist at an academic institution

Ticker(s): AIMT, DBVT

Who's the expert?

Name: Dr John Lee - MD

Institution: Boston Children's | Harvard

  • Clinical Director, Food Allergy Program; Allergy Director, Eosinophilic Gastrointestinal Disease (EGID) Program at Boston Children's & Instructor in Pediatrics, Harvard Medical School.
  • Currently manages 500-750 patients with peanut allergy and 500 children with milk allergy.
  • Co-investigators in food allergy desensitization programs at Boston Children's Hospital & co-creator of AllergyHome.org.

Interview Questions
Q1.

What % of your patients would you anticipate wanting to use AR101 if approved?

Added By: joe_mccann
Q2.

Can you give us your opinion as to how the safety vs benefit balance between the two drugs?

Added By: joe_mccann
Q3.

Is there still a need for a different treatment option or do these two potential entries to market cover most all patient cases you see?

Added By: joe_mccann
Q4.

How does the route of administration factor into treatment decision making?  more specifically, for the pediatric audience?  

Added By: joe_mccann
Q5.

Please describe your clinical background and how you currently manage your peanut allergy patients.

Added By: joe_mccann
Q6.

Will  there be options for patients using one product to be able to switch to another product during maintenance phase? 

Added By: userb298024d
Q7.

Will there be room in the market for additional products targeting peanut allergy?  For example, one company has recently announced a toothpaste containing peanut proteins, which may support long term maintainence.

Added By: userb298024d

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.